WHO recommends corticosteroids for patients with severe or critical COVID-19

Area of Science:

• Infectious Diseases
• Pharmacology
• Public Health

Background:

• The COVID-19 pandemic necessitated rapid development and evaluation of therapeutic agents.
• Clinical practice guidelines are essential for evidence-based management of emerging infectious diseases.
• The World Health Organization (WHO) plays a critical role in global health recommendations.

Purpose of the Study:

• To provide a continuously updated guideline on drug therapies for COVID-19.
• To synthesize emerging evidence on the efficacy and safety of various treatments.
• To support clinicians in making optimal treatment choices for COVID-19 patients.

Main Methods:

• Systematic reviews and meta-analyses of randomized controlled trials (RCTs) were conducted.
• The guideline development process followed rigorous methodologies, including GRADE.
• Living guideline approach ensured timely updates as new evidence emerged.

Main Results:

• Recommendations were provided for several drug classes, including antivirals and immunomodulators.
• The guideline addressed the use of specific drugs like remdesivir, hydroxychloroquine, lopinavir/ritonavir, and others.
• Conditional or strong recommendations were issued based on the quality of evidence and patient values.

Conclusions:

• Living guidelines are crucial for managing rapidly evolving diseases like COVID-19.
• Evidence-based recommendations help standardize care and improve patient outcomes.
• Continuous evaluation of treatments ensures that guidelines remain relevant and reflect the latest scientific understanding.